Clinical Trial

A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Activity of GDC-1261 in Participants With Advanced or Metastatic Prostate Cancer

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the safety, pharmacokinetics (PK), and preliminary activity of GDC-1261 in participants with advanced or metastatic prostate cancer. It's also to identify a recommended dose(s) and regimen for GDC-1261 for subsequent studies.
Protocol Amendment History 1 change
critical Recruitment opened 2026-06-12
Trial Details
NCT Number NCT07567846
Lead Sponsor Genentech, Inc.
Conditions Advanced Prostate Cancer, Metastatic Prostate Cancer
Enrollment 260 participants
Start Date 2026-04-29
Primary Completion 2027-11-30 (estimated)
Study Completion 2027-12-30 (estimated)
Updated on ClinicalTrials.gov 2026-08-10